|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cardoso F, Paluch-Shimon S, Senkus E,
Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya
GS, Biganzoli L, et al: 5th ESO-ESMO international consensus
guidelines for advanced breast cancer (ABC 5). Ann Oncol.
31:1623–1649. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Finn RS, Crown JP, Lang I, Boer K,
Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et
al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in
combination with letrozole versus letrozole alone as first-line
treatment of oestrogen receptor-positive, HER2-negative, advanced
breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study.
Lancet Oncol. 16:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cristofanilli M, Turner NC, Bondarenko I,
Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et
al: Fulvestrant plus palbociclib versus fulvestrant plus placebo
for treatment of hormone-receptor-positive, HER2-negative
metastatic breast cancer that progressed on previous endocrine
therapy (PALOMA-3): Final analysis of the multicentre,
double-blind, phase 3 randomised controlled trial. Lancet Oncol.
17:425–439. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hortobagyi GN, Stemmer SM, Burris HA, Yap
YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell
KL, Winer EP, et al: Updated results from MONALEESA-2, a phase III
trial of first-line ribociclib plus letrozole versus placebo plus
letrozole in hormone receptor-positive, HER2-negative advanced
breast cancer. Ann Oncol. 29:1541–1547. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slamon DJ, Neven P, Chia S, Fasching PA,
De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín
M, et al: Phase III randomized study of ribociclib and fulvestrant
in hormone receptor-positive, human epidermal growth factor
receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin
Oncol. 36:2465–2472. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goetz MP, Toi M, Campone M, Sohn J,
Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, et
al: MONARCH 3: Abemaciclib as initial therapy for advanced breast
cancer. J Clin Oncol. 35:3638–3646. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sledge GW Jr, Toi M, Neven P, Sohn J,
Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al:
The effect of abemaciclib plus fulvestrant on overall survival in
hormone receptor-positive, ERBB2-negative breast cancer that
progressed on endocrine therapy-MONARCH 2: A Randomized Clinical
Trial. JAMA Oncol. 6:116–124. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schettini F, Giudici F, Giuliano M,
Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S,
Paris I, De Placido P, et al: Overall survival of
CDK4/6-inhibitor-based treatments in clinically relevant subgroups
of metastatic breast cancer: Systematic review and meta-analysis. J
Natl Cancer Inst. 112:1089–1097. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Migliaccio I, Leo A, Galardi F, Guarducci
C, Fusco GM, Benelli M, Di Leo A, Biganzoli L and Malorni L:
Circulating biomarkers of CDK4/6 inhibitors response in hormone
receptor positive and HER2 negative breast cancer. Cancers (Basel).
13:26402021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cézé N, Thibault G, Goujon G, Viguier J,
Watier H, Dorval E and Lecomte T: Pre-treatment lymphopenia as a
prognostic biomarker in colorectal cancer patients receiving
chemotherapy. Cancer Chemother Pharmacol. 68:1305–1313. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grossman SA, Ye X, Lesser G, Sloan A,
Carraway H, Desideri S and Piantadosi S; NABTT CNS Consortium, :
Immunosuppression in patients with high-grade gliomas treated with
radiation and temozolomide. Clin Cancer Res. 17:5473–5480. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Balmanoukian A, Ye X, Herman J, Laheru D
and Grossman SA: The association between treatment-related
lymphopenia and survival in newly diagnosed patients with resected
adenocarcinoma of the pancreas. Cancer Invest. 30:571–576. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He JR, Shen GP, Ren ZF, Qin H, Cui C,
Zhang Y, Zeng YX and Jia WH: Pretreatment levels of peripheral
neutrophils and lymphocytes as independent prognostic factors in
patients with nasopharyngeal carcinoma. Head Neck. 34:1769–1776.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kobayashi N, Usui S, Kikuchi S, Goto Y,
Sakai M, Onizuka M and Sato Y: Preoperative lymphocyte count is an
independent prognostic factor in node-negative non-small cell lung
cancer. Lung Cancer. 75:223–227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feng JF, Liu JS and Huang Y: Lymphopenia
predicts poor prognosis in patients with esophageal squamous cell
carcinoma. Medicine (Baltimore). 93:e2572014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ray-Coquard I, Cropet C, Van Glabbeke M,
Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P,
Labidi I, et al: European Organization for Research and Treatment
of Cancer Soft Tissue and Bone Sarcoma Group: Lymphopenia as a
prognostic factor for overall survival in advanced carcinomas,
sarcomas, and lymphomas. Cancer Res. 69:5383–5391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schwartz LH, Seymour L, Litière S, Ford R,
Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et
al: RECIST 1.1 - Standardisation and disease-specific adaptations:
Perspectives from the RECIST Working Group. Eur J Cancer.
62:138–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
US Department of Health Human Services:
Common Terminology Criteria for Adverse Events (CTCAE).v.5.0. Natl
Institutes Heal Natl Cancer Institute. p1552017.PubMed/NCBI
|
|
20
|
Garrido-Castro AC and Goel S: CDK4/6
inhibition in breast cancer: Mechanisms of response and treatment
failure. Curr Breast Cancer Rep. 9:26–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rosenberg SA: The immunotherapy of solid
cancers based on cloning the genes encoding tumor-rejection
antigens. Annu Rev Med. 47:481–491. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bates GJ, Fox SB, Han C, Leek RD, Garcia
JF, Harris AL and Banham AH: Quantification of regulatory T cells
enables the identification of high-risk breast cancer patients and
those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schreiber RD, Old L and Smyth MJ: Cancer
immunoediting: Integrating immunity's roles in cancer suppression
and promotion. Science. 331:1565–7150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ray-Coquard I, Ghesquière H, Bachelot T,
Borg C, Biron P, Sebban C, LeCesne A, Chauvin F and Blay JY; ELYPSE
Study Group, : Identification of patients at risk for early death
after conventional chemotherapy in solid tumours and lymphomas. Br
J Cancer. 85:816–822. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ray-Coquard I, Borg C, Bachelot T, Sebban
C, Philip I, Clapisson G, Le Cesne A, Biron P, Chauvin F and Blay
JY; ELYPSE study group, : Baseline and early lymphopenia predict
for the risk of febrile neutropenia after chemotherapy. Br J
Cancer. 88:181–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lissoni P, Brivio F, Fumagalli L, Messina
G, Ghezzi V, Frontini L, Giani L, Vaghi M, Ardizzoia A and Gardani
GS: Efficacy of cancer chemotherapy in relation to the pretreatment
number of lymphocytes in patients with metastatic solid tumors. Int
J Biol Markers. 19:135–140. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Franks CR and Williams Y: Prognostic value
of peripheral lymphocyte count in hormone therapy of advanced
breast cancer. Br J Cancer. 34:641–644. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Limori N, Shinichiro K, Yuka A, Wataru G,
Koji T, Katsuyuki T and Takaharu H: Clinical significance of the
neutrophil-to-lymphocyte ratio in endocrine therapy for stage IV
breast cancer. In Vivo. 32:669–675. 2018.PubMed/NCBI
|
|
30
|
Gobert M, Treilleux I, Bendriss-Vermare N,
Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I,
Olive D, et al: Regulatory T cells recruited through CCL22/CCR4 are
selectively activated in lymphoid infiltrates surrounding primary
breast tumors and lead to an adverse clinical outcome. Cancer Res.
69:2000–2009. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang Y: Cancer immunotherapy: Harnessing
the immune system to battle cancer. J Clin Invest. 125:3335–3337.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goel S, DeCristo MJ, Watt AC, BrinJones H,
Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, et
al: CDK4/6 inhibition triggers anti-tumour immunity. Nature.
548:471–475. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lelliott EJ, Kong IY, Zethoven M,
Ramsbottom KM, Martelotto LG, Meyran D, Zhu JJ, Costacurta M, Kirby
L, Sandow JJ, et al: CDK4/6 inhibition promotes antitumor immunity
through the induction of T-cell memory. Cancer Discov. May
14–2021.doi: 10.1158/2159-8290.CD-20-1554. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang QF, Li J, Jiang K, Wang R, Ge JL,
Yang H, Liu SJ, Jia LT, Wang L and Chen BL: CDK4/6 inhibition
promotes immune infiltration in ovarian cancer and synergizes with
PD-1 blockade in a B cell-dependent manner. Theranostics.
10:10619–10633. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Teh JL and Aplin AE: Arrested
developments: CDK4/6 inhibitor resistance and alterations in the
tumor immune microenvironment. Clin Cancer Res. 25:921–927. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Deng J, Wang ES, Jenkins RW, Li S, Dries
R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, et al: CDK4/6
inhibition augments antitumor immunity by enhancing T-cell
activation. Cancer Discov. 8:216–233. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Williams KM, Hakim FT and Gress RE: T cell
immune reconstitution following lymphodepletion. Semin Immunol.
19:318–330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ménétrier-Caux C, Ray-Coquard I, Blay JY
and Caux C: Lymphopenia in cancer patients and its effects on
response to immunotherapy: An opportunity for combination with
Cytokines? J Immunother Cancer. 7:852019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ferrando-Martínez S, Franco JM, Hernandez
A, Ordoñez A, Gutierrez E, Abad A and Leal M: Thymopoiesis in
elderly human is associated with systemic inflammatory status. Age
(Dordr). 31:87–97. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Manuel M, Tredan O, Bachelot T, Clapisson
G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret
JF, et al: Lymphopenia combined with low TCR diversity (divpenia)
predicts poor overall survival in metastatic breast cancer
patients. OncoImmunology. 1:432–440. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Degrassat-Théas A, Paubel P, Parent de
Curzon O, Le Pen C and Sinègre M: Temporary authorization for use:
Does the French patient access programme for unlicensed medicines
impact market access after formal licensing? PharmacoEconomics.
31:335–343. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Battisti NM, Kingston B, King J, Denton A,
Waters S, Sita-Lumsden A, Rehman F, Stavraka C, Kristeleit H,
Sawyer E, et al: Palbociclib and endocrine therapy in heavily
pretreated hormone receptor-positive HER2-negative advanced breast
cancer: The UK Compassionate Access Programme experience. Breast
Cancer Res Treat. 174:731–740. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Blay J, Ray-Coquard I and Mermet C: A
multicentric prospective study of prognostic factors for febrile
neutropenia after chemotherapy in general and cancer hospitals. J
Clin Oncol. 16:56a1997.
|
|
44
|
Blay JY, Le Cesne A, Mermet C, Maugard C,
Ravaud A, Chevreau C, Sebban C, Guastalla J, Biron P and
Ray-Coquard I: A risk model for thrombocytopenia requiring platelet
transfusion after cytotoxic chemotherapy. Blood. 92:405–410. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Borg C, Ray-Coquard I, Philip I, Clapisson
G, Bendriss-Vermare N, Menetrier-Caux C, Sebban C, Biron P and Blay
JY: CD4 lymphopenia as a risk factor for febrile neutropenia and
early death after cytotoxic chemotherapy in adult patients with
cancer. Cancer. 101:2675–2680. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Moftakhar B, Lekkala M, Strawderman M,
Smith TC, Meacham P, Fitzgerald B, Falkson CI and Dhakal A: Impact
of early dose intensity reduction of Palbociclib on clinical
outcomes in patients with hormone-receptor-positive metastatic
breast cancer. Breast Cancer Res Treat. 183:411–418. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Groenland SL, Martínez-Chávez A, van
Dongen MG, Beijnen JH, Schinkel AH, Huitema AD and Steeghs N:
Clinical Pharmacokinetics and Pharmacodynamics of the
Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib,
and Abemaciclib. Clin Pharmacokinet. 59:1501–1520. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
O'Leary B, Cutts RJ, Huang X, Hrebien S,
Liu Y, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M,
et al: Circulating tumor DNA markers for early progression on
fulvestrant with or without palbociclib in ER+ advanced
breast cancer. J Natl Cancer Inst. 113:309–317. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Che YQ, Zhang Y, Wang D, Liu H-Y, Shen D
and Luo Y: Baseline lymphopenia: A predictor of poor outcomes in
HER2 positive metastatic breast cancer treated with trastuzumab.
Drug Des Devel Ther. 13:3727–3734. 2019. View Article : Google Scholar : PubMed/NCBI
|
